Recommended Products
Assay
≥95% (SDS-PAGE)
Quality Level
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
impurities
≤100 pg/μg Endotoxins (pg/μg Angiogenin)
shipped in
dry ice
storage temp.
−70°C
General description
Recombinant, human angiogenin expressed in E. coli. A 14 kDa protein with angeogenic and ribonucleolytic activities. Enhances the proteolytic and fibrinolytic activities of endothelial cells. Also, stimulates the endothelial cell invasion of Matrigel basement membrane. Has been shown to stimulate capillary and umbilical vein endothelial cells to produce DAG and secrete prostacyclin by phospholipase activation.
Recombinant, human angiogenin expressed in E. coli. Exhibits angiogenic and ribonucleolytic activities. Enhances the ability of endothelial cells to digest extracellular matrix components and degrade basement membrane. Has been shown to stimulate capillary and umbilical vein endothelial cells to produce DAG and secrete prostacyclin by phospholipase activation. Biological activity: 1.0 µg protein produces an absorbance change at 260 nm of approximately 2.0 - 3.0 as measured by yeast tRNA ribonucleolytic activity.
Biochem/physiol Actions
≥1.0 µg protein produces an absorbance change at 260 nm of ~2.0-3.0 as measured based upon its ribonucleolytic activity toward Yeast tRNA.
Warning
Toxicity: Standard Handling (A)
Physical form
Lyophilized from sterile-filtered PBS containing 50 µg BSA/µg Angiogenin.
Reconstitution
Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to months at -70°C. Avoid freeze/thaw cycles of solutions.
Reconstitute to a concentration ≥1 µg/ml with sterile PBS containing ≥0.1% HSA or BSA.
Other Notes
Leland, P.A., et al. 2002. Biochemistry41, 1343.
Hatzi, E., et al. 2000. Biochem. Biophys. Res. Commun. 267, 719.
Hu, G., et al. 1994. Proc. Natl. Acad. Sci. USA91, 12096.
Lee, F.S., and Vallee, B.L. 1989. Biochem. Biophys. Res. Commun.161, 121.
Kurachi, R., et al. 1985. Biochemistry24, 5494.
Hatzi, E., et al. 2000. Biochem. Biophys. Res. Commun. 267, 719.
Hu, G., et al. 1994. Proc. Natl. Acad. Sci. USA91, 12096.
Lee, F.S., and Vallee, B.L. 1989. Biochem. Biophys. Res. Commun.161, 121.
Kurachi, R., et al. 1985. Biochemistry24, 5494.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jürgen Krauss et al.
Methods in molecular biology (Clifton, N.J.), 525, 471-490 (2009-03-03)
ImmunoRNases represent a highly attractive alternative to conventional immunotoxins for cancer therapy. Quantitative production of immunoRNases in appropriate expression systems, however, remains a major challenge for further clinical development of these novel compounds. Here we describe a method for high-level
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service